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Available online 9 September 2016Background:Xerostomia is a chief complaint of patientswith Sjögren's syndrome (SS). However, newer proposals
for SS classiﬁcation remove xerostomia and hyposalivation from the criteria list. Given these developments and
the importance of patient-centered research outcomes, we sought to evaluate the utility of patient-reported
xerostomia with implications for classiﬁcation criteria, and clinical trials targeting SS treatment modalities.
Methods: A nested case-control study was designed within The National Institute of Dental and Craniofacial Re-
search/National Institutes of Health (NIDCR/NIH) SS Cohort - one of the largest SS cohorts in theUS. Clinical char-
acteristics of those with and without xerostomia in SS and other salivary gland dysfunctions were compared.
Several analytical methods were employed, including multivariable logistic regression modeling.
Findings: TheNIDCR/NIH Sjögren's Syndrome Clinic has an open cohortwith ongoing enrollment since 1984. This
open cohort comprised of 2046 participants by August 27, 2015. Baseline data of 701 SS, 355 Sicca, and 247 ISS
participants within the source cohort were analyzed. Xerostomia was highest among SS participants (87.4%,
95% CI: 84.8%–89.8%) compared to Sicca (72.4%, 95% CI: 67.4%–77.0%, p b 0.001) and ISS groups (38.1%, 95% CI:
32.0%–44.4%, p b 0.001). Those with xerostomia were more likely to have SS than Sicca/ISS (OR = 4.98, 95%
CI: 3.78–6.56). The ability of xerostomia to screen for SS among those with salivary gland dysfunctionwas higher
than screening for Sicca/ISS. Screening diagnostics of xerostomia were of greater utility compared to
hyposalivation. After adjusting for confounding in multivariable modeling, SS participants with xerostomia
weremore likely to beWhite (Black/AfricanAmericans (OR: 0.40, 95% CI: 0.23–0.68, p-value=0.001) andAsians
(OR: 0.49, 95% CI: 0.25–0.96, p-value=0.038)were less likely to have xerostomia compared toWhites), have dry
eye symptoms for N3 months (OR: 5.80, 95% CI: 3.62–9.28, p-value b0.001), a lower Van Bijsterveld score (OR:
0.55, 95%CI: 0.34–0.90, p-value = 0.017), a lower stimulated salivary ﬂow rate (OR: 1.67, 95% CI: 1.06–2.65, p-
value = 0.028), a focus score of N2 (OR: 1.92, 95% CI: 1.20–3.09, p-value = 0.007), and salivary gland swelling
(OR: 49.39, 95% CI: 2.02–1206.30, p-value = 0.017). Age, gender, fatigue, pain, anxiety, and autoantibodies
were not signiﬁcantly associated with xerostomia.
Interpretation: Findings from this study indicate that patient-reported xerostomia is highly prevalent among SS
patients and is associated with several clinical phenotypes of this complex syndrome, thereby making it an im-
portant indicator of SS. The evidence also suggests that xerostomia is not limited to low salivary ﬂow but
might be reﬂective of compositional changes of saliva. Consequently, these ﬁndings suggest the need to consider
xerostomia in the development of SS classiﬁcation criteria and in patient-centered outcomes research in SS inter-
vention trials.
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In 1933, Henrik Sjögren, in his doctoral dissertation introduced the
neologism, keratoconjunctivitis Sicca (Murube, 2010, Sjögren, 1933).
His ﬁndings now known as Sjögren's syndrome (SS), has come to beense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the salivary and lacrimal glands, presenting with oral and ocular dry-
ness, and often accompanied by extraglandular manifestations. Lym-
phocytic inﬁltration of the salivary glands has been a hallmark ﬁnding.
However, the dysregulated immune response and salivary gland dys-
function are not always correlated and salivary gland dysfunction
could precede autoimmunity or even be a result of an independent pro-
cess in the pathogenesis of this syndrome (Nikolov and Illei, 2009). Sev-
eralmodels of pathogenesis have been proposed, involving genetics, the
environment, the innate and adaptive immune system, the autonomic
nervous system, hormonal factors, or an interplay of these factors
(Nikolov and Illei, 2009, Lessard, 2013, Burbelo et al., 2014, Iwakiri et
al., 2009, Deshmukh et al., 2009, Zheng et al., 2010, Alevizos et al.,
2011, Nocturne and Mariette, 2013, Gabor Illei. and Alevizos, 2013
Hernandez-Molina et al., 2011, Valtysdottir et al., 2001, Laine et al.,
2007, Porola et al., 2008, Forsblad-d'Elia et al., 2009, Cai et al., 2008,
Barendregt et al., 1998, Mandl et al., 2007, Andonopoulos et al., 1998).
Since ﬁrst described by Henrik Sjögren, the chief oral complaint of
individuals with SS most commonly has been the symptom of dry
mouth or xerostomia, associated with signiﬁcant morbidity and affect-
ing the oral-health-related quality of life of patients (Sjögren, 1933,
Visvanathan and Nix, 2010, Fox et al., 2008, Napenas and Rouleau,
2014, Ying Joanna and Thomson, 2015). However, patient-reported
xerostomia is not an exclusive characteristic of Sjögren's syndrome,
but could be a result of other conditions (Manuel Ramos-Casals and
Moutsopoulos, 2012, Porter and Scully, 2000, Sreebny and Schwartz,
1997, Rad et al., 2010). This subjective complaint of xerostomia does
not necessarily correlate with objective measures of hyposalivation
(Manuel Ramos-Casals and Moutsopoulos, 2012, Fox et al., 1985, Ying
Joanna and Thomson, 2015). Rather, xerostomia has been found to be
associated with compositional changes of saliva (Alliende et al., 2008).
Studies have also shown differences in the composition of stimulated
saliva from the major salivary glands in patients with SS compared to
healthy controls, and there is no correlation between compositional
changes of stimulated saliva and salivary ﬂow rates (Atkinson et al.,
1990, Kalk et al., 2002, Mathews et al., 2008, Helenius et al., 2005).
Xerostomia is also dependent on individual patient thresholds for oral
dryness, tolerance, and adaptation (Manuel Ramos-Casals and
Moutsopoulos, 2012, Scully and Felix, 2005).
Recently, new classiﬁcation criteria for SS have been proposed
(Shiboski et al., 2012).While the current American-European consensus
classiﬁcation criteria for SS include xerostomia and hyposalivation in
the assessment algorithm, the new classiﬁcation set does not
(Shiboski et al., 2012, Vitali et al., 2002). Consequently, salivary gland in-
volvement in SS is assessed partially by the new criteria by the presence
of focal lymphocytic sialadenitis (Daniels et al., 2011). Therefore, the
new approach to classiﬁcation has a potential for misclassiﬁcation and
for missing cases that are in an early stage of disease progression
(Vitali et al., 2013).
Given that xerostomia is a chief oral complaint of patients with SS
and the assessment of salivary gland dysfunction is essential for diagno-
sis, we sought to investigate whether patient-reported xerostomia is
still a valuable classiﬁcation criterion and an important end-point in
clinical trials targeting treatment modalities for SS (Aim-1). Further-
more, evaluation of this objective would be important if xerostomia is
a composite indicator of various factors functioningwithin this complex
syndrome, capturing factors such as salivary gland dysfunction
expressed as compositional changes of saliva, and underlying pathways
of pathogenesis including, but not limited to lymphocytic inﬁltration.
Next, we wanted to evaluate xerostomia-related factors that impact
screening for SS (Aim-2). Consequently,we sought to determine test ac-
curacy measurements of xerostomia as a screening aid for SS among
those with salivary gland dysfunction. Test accuracy measurements of
hyposalivation were also determined for comparison. Finally, we
wanted to ascertain similarities and differences in the clinical character-
istics of those with and without xerostomia among those diagnosedwith SS, and also among those with other salivary gland dysfunction
for comparison (Aim-3).
2. Materials & Methods
2.1. Study Population
The NIDCR Sjögren's Syndrome and Salivary Gland Dysfunction Unit
(SSGDU) has been evaluating and enrolling participants with clinical
suspicion of SS or salivary gland dysfunction since 1984, making the
NIDCR/NIH SS cohort one of the largest in the US. To investigate the pro-
posed objectives we designed a nested case-control study within the
overall cohort comprising all participants enrolled before August 27,
2015.
2.2. Main Outcome Variables
We compared three groups (SS, Sicca, ISS) at high-risk for salivary
gland dysfunction. SS was deﬁned according to the American-European
consensus group classiﬁcation criteria (AECG) (Vitali et al., 2002). Sicca
was deﬁned as the presence of oral dryness determined by a whole
unstimulated salivary ﬂow rate (WUS) of ≤1.5ml/15min or ocular dry-
ness determined by a Schirmer's test of ≤5mm/5min without anesthe-
sia or Van Bijsterveld score of ≥4 in at least one eye, with the absence of
focal lymphocytic sialadenitis (focus score b 1 per 4 mm2) and the ab-
sence of anti-SSA (Ro) and anti-SSB (La) autoantibodies. The oral dry-
ness experienced in the Sicca group would be due to salivary gland
dysfunction other than SS. This could include developmental causes
(e.g. salivary gland aplasia), iatrogenic (e.g. postsurgical), inﬂammatory
(e.g. IgG4-related disease), neoplastic, sialolithiasis, or systemic causes
(e.g. diabetes mellitus). Incomplete Sjögren's syndrome (ISS) was de-
ﬁned as the presence of a focus score of ≥1 per 4mm2 or autoantibodies
SSA or SSB but not meeting the AECG criteria for SS classiﬁcation.
2.3. Main Exposure Variables
Xerostomia was deﬁned as patient-reported daily feeling of dry
mouth for more than three months. Hyposalivation was deﬁned as
WUS of 1.5 ml/15 min or lower (Vitali et al., 2002). Data were imputed
with total unstimulated salivary ﬂow rate (TUS), which is the sumof pa-
rotid and submandibular/sublingual unstimulated salivary ﬂow, for
missing WUS. This combination of WUS and imputed TUS was termed
as imputed unstimulated salivary ﬂow rate (IUS); for TUS and IUS a
cut off threshold of ≤1.5 ml/15 min was set to indicate hyposalivation.
Analyses were undertaken with WUS, TUS, and IUS separately. Stimu-
lated salivary ﬂow rates were modeled with a ﬂow rate of ≤7.5 ml/
15 min representing salivary dysfunction (Manuel Ramos-Casals and
Moutsopoulos, 2012).
2.4. Covariates
Demographic data on age, gender, race, and ethnicity of participants
were collected. Current use of medications was categorized into ﬁve
mutually exclusive categories: i) medications that reduce salivary
ﬂow, ii) sialagogues, iii) medications for extraglandular manifestations,
iv) combination of medications of the three categories, and v) other
medications. Autonomic nervous system assessment was undertaken,
inwhich, patient-reported fatigue and anxietywere deﬁned as the pres-
ence of any number of episodes of fatigue or anxiety in amonth or daily.
Brief pain inventory was ascertained. Past medical history of thyroid
disease and diabetes mellitus type I and II was also ascertained. Ciga-
rette smoking, alcohol use, and caffeine use status was deﬁned as any
use of cigarettes, any alcoholic drinks per week, and one or more caf-
feinated beverages per day respectively.
272 M. Billings et al. / EBioMedicine 12 (2016) 270–2792.5. Study Procedures
A comprehensive oral and medical history was recorded. Head and
neck and oral examination, and physical examination were performed.
Salivary gland function evaluation (unstimulated followed by stimulat-
ed salivary ﬂow rates), labialminor salivary gland biopsy, assessment of
lacrimal function and standard eye examinations were performed. The
vanBijsterveld andOxford scores based on lissamine greenwere the oc-
ular scoring systems used in this study. Clinical laboratory studies were
done to test the general health of the participant and to assess for auto-
immunemarkers. Testing for hepatitis B and C, and HIVwas also under-
taken. All study participants provided Informed Consent prior to the
initiation of any study procedures and clinical protocols were approved
by the NIH Institutional Review Board, conforming to the standards in-
dicated by the Declaration of Helsinki.
2.6. Bias Assessment
Selection of SS, Sicca, and ISS participants was based on standard
criteria (AE classiﬁcation criteria) and objective tests irrespective of
xerostomia status rendering the study to be devoid of selection bias.
Furthermore, selection bias is diminished when cases and controls are
selected from a deﬁned cohort compared to the traditional case-control
study design. As the exposure of interest, xerostomia is of considerable
duration (N3 months) the introduction of recall bias and subsequent
misclassiﬁcation is not possible. The study design is also not jeopardized
bymisclassiﬁcation of outcomes of interest (SS, Sicca and ISS), as the de-
tection of these high-risk groups was based on standard, accepted
criteria and objective tests, and was ascertained prior to establishing
study objectives. Therefore, observer/investigator bias was avoided.
Screening tests were applied to only the three high-risk groups and
not normal volunteers, as were all comparative analyses; therefore,
the exaggeration of the magnitude of association of any risk factor was
avoided. No postulation of causation was set and therefore temporal
bias does not play a role in the interpretation of results. The validity of
comparison between cases (SS) and controls (Sicca and ISS) regarding
exposure status (xerostomia) in this nested case-control study is justi-
ﬁed by the use of a deﬁned source cohort fromwhich cases and controls
were selected during the same study period.
2.7. Statistical Methods
Baseline data of all variables of interest were analyzed. A statistical
signiﬁcance level of α = 0.05 was chosen. Descriptive data analysis
was performed using standard summary statistics. Exploratory data
analyses were performed on all variables of interest, including checks
for normality (Shapiro Wilk test) and equal variance (Levene's test).
Non parametric tests (Mann-WhitneyU) were employedwhen indicat-
ed. Sensitivity and speciﬁcity analyseswere conducted. Two sample test
of proportions were carried out. Correlations were assessed with Point-
biserial correlation coefﬁcient. Correlation coefﬁcients were computed
including and excluding outliers as outliers are known to inﬂuence the
correlation coefﬁcient by rendering it non-signiﬁcant. An outlier was
determined as any data point N1.5 times the interquartile range (IQR)
below the ﬁrst quartile or above the third quartile of the data. Total ef-
fects were studied by simple logistic regressionmodels. Multivariate lo-
gistic regression models were constructed after checking for
collinearity. Models by various methods (forward and backward step-
wise, and likelihood ratio testing) were compared to check for consis-
tency of results. Apart from model-selected variables, variables of
interest were locked into the model. Forward stepwise selection with
correction for dispersion determined the ﬁnal model. Statistical signiﬁ-
cancewas assessed on a set two-tailed p-value of 0.05. Non- statistically
signiﬁcant variables were veriﬁed by testparm. Checks for pertinent in-
teractions/effect modiﬁcation were undertaken. Goodness of ﬁt of the
ﬁnal model was assessed using Hosmer-Lemeshow test. All statisticalanalyses were performed using STATA 14.0 (StataCorp. 2015. Stata Sta-
tistical Software: Release 14. College Station, TX: StataCorp LP).
3. Results
As of August 27, 2015, the SSGDU at NIDCR/NIH has evaluated 3349
and enrolled 2046 participants. In this study, we compared baseline
data of three groups at high-risk for salivary gland dysfunction with
701 SS, 355 Sicca, and 247 ISS participants (Fig. 1). Demographic charac-
teristics of these groups were assessed, stratiﬁed by the presence or ab-
sence of xerostomia (Table 1). In the SS group, age, race and ethnicity
were signiﬁcantly different between those with and without
xerostomia. In the Sicca group, differences in gender and ethnicity
were statistically signiﬁcant and in the ISS group, no differences in de-
mographics by xerostomia status were found. The three groups, SS,
Sicca, and ISS differed in the prevalence of key characteristics, i.e.,
xerostomia, positive focus score, and positive serology (Supporting In-
formation (SI)), with the SS group having the highest prevalence of
these characteristics. The duration of drymouth symptoms also differed
across groups with the SS group having the longest median duration
(SI).
Among the 1303 participants in our study, 74% (n = 964) reported
xerostomia (Table 2). Xerostomia prevalence was highest among SS
participants (87.4%, 95% CI: 84.8%–89.8%) followed by Sicca participants
(72.4%, 95% CI: 67.4%–77.0%) and the ISS group (38.1%, 95% CI: 32.0%–
44.4%). The absolute difference in xerostomia prevalence between SS
and Sicca participants was signiﬁcant (15.0%, 95% CI: 9.8%–20.3%,
p b 0.001) as was the absolute difference in prevalence between SS
and ISS participants (49.4%, 95% CI: 42.9%–55.9%, p b 0.001).
The sensitivity of xerostomia for detecting SS among high-risk par-
ticipants was 87.4% (95% CI: 84.8%–89.8%) and speciﬁcity was 41.7%
(95% CI: 37.7%–45.7%) (Table 2A). SS participants were 50% more likely
to have xerostomia compared to other high risk participants, namely
Sicca and ISS (LR+ = 1.50, 95% CI: 1.39–1.61). Moreover, SS partici-
pants were 70% less likely to be without xerostomia compared to
other high risk participants (LR−= 0.30, 95% CI: 0.24–0.37). Further,
SS participants had a 5-fold higher risk of xerostomia compared to
other high-risk participants (OR = 4.98, 95% CI: 3.78–6.56). Conse-
quently, a participant with salivary gland dysfunction presenting with
xerostomia is 5 times more likely to have SS than Sicca or ISS. The pos-
itive predictive value (PPV) and negative predictive value (NPV) of
xerostomia indicate that a high-risk participant with xerostomia has a
64% chance of having SS, and if without xerostomia, has a 74% chance
of not having SS.
In contrast, Sicca and ISS participants had a lower likelihood of hav-
ing xerostomia and a higher likelihood of being without xerostomia
compared to SS participants. The odds ratios of having xerostomia in
Sicca and ISS compared to SS participants were signiﬁcantly lower, indi-
cating the utility of xerostomia for distinguishing between SS and other
high-risk participants. The PPV and NPV of xerostomia in Sicca and ISS
participants were also signiﬁcantly lower than that seen in SS partici-
pants. Given these test statistics, among high-risk participants, pa-
tient-reported xerostomia was a better screening aid for SS than for
Sicca or ISS, and therefore a better indicator of SS.
Unlike xerostomia which is subjective, hyposalivation is a quantiﬁ-
able measure. Test diagnostics indicated the sensitivity of WUS for de-
tecting SS was 63.8% (95% CI: 56.3%–70.9%) while the speciﬁcity was
51.3% (95% CI: 43.1%–59.4%). The OR, PPV, and NPV test statistics for
WUS in detecting SS were lower compared to those of xerostomia. Al-
though SS participants were 50% more likely to have xerostomia com-
pared to other high-risk participants, WUS as a screening test was
unable to differentiate between SS and Sicca (overlapping 95% CIs,
Table 2A) and test diagnostics for ISS were low. For IUS, sensitivity
was 76% and speciﬁcity was 46.9% for detecting SS and SS participants
were nearly 3 times more likely to have xerostomia compared to
other high-risk groups (OR = 2.80, 95% CI: 2.17–3.62). The inability of
Fig. 1. Enrollment ﬂow diagram. *Based on study's exclusion criteria: those under 4 years of age, diagnosed with drug-related xerostomia, unable or unwilling to comply with follow-up
requirements, with any medical or psychological/psychiatric condition or treatment that would exclude them from the research, and unable to give consent/assent or parental/guardian
consent. **Includes those whomeet AE classiﬁcation exclusion criteria and those who have incomplete information to date to classify. SS: Sjögren's Syndrome | ISS: Incomplete Sjögren's
Syndrome | NV: Normal Volunteers. Participants, though not restricted to enroll based on geographic region or countries, were predominately from the Eastern US of varied races and
ethnicities. They were referred by private physicians and dentists, the National Institutes of Health (NIH) Clinical Center, or self- referred. All participants were enrolled in NIH
Institutional Review Board approved Clinical Protocols and had provided Informed Consent prior to the initiation of any study procedures.
Adapted from PRISMA Statement.
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tics was corroborated by the non-statistically signiﬁcant difference in
medianWUSbetween the SS and Sicca groups (Figs. 2, 3). As the test di-
agnostics of IUS were better than that of WUS, we also found that the
median IUS was signiﬁcantly different among all 3 high-risk groups.
The SS group had the lowest median IUS and TSS compared to Sicca
and ISS groups.
Correlations between WUS, IUS, TSS, and Xerostomia are shown in
Table 2B. In the overall pool of high-risk participants, both unstimulated
and stimulated salivary ﬂow rates were negatively correlated with
xerostomia, with WUS possessing the strongest point-biserial correla-
tion coefﬁcient compared to IUS and TSS (−0.49, −0.42, −0.21Table 1
Comparison of demographic characteristics of high-risk groups by xerostomia status.
aWilcoxon rank-sum (Mann-Whitney) test | bFisher exact test | cAmerican Indian or Alaskan Na
centages rounded to one decimal place.
Demographic characteristic
SS+X+ SS+X−
p-Value
Sicca+
N = 613 N = 88 N = 25
Age (median, range) 53 (7–81) 48 (16–83) 0.001a 52 (17–
Gender (n, %)
Male 48 (7.8) 9 (10.2) 0.41b 37 (14.
Female 565 (92.2) 79 (89.8) 220 (85
Race (n, %)
White 455 (74.2) 50 (56.8) 0.01b 225 (87
Black or African American 73 (11.9) 20 (22.7) 15 (5.8
Asian 44 (7.2) 11 (12.5) 9 (3.5)
Otherc 41 (6.7) 7 (8.0) 8 (3.1)
Ethnicity (n, %)
Not Latino or Hispanic 564 (92.0) 79 (89.8) 0.03b 253 (98
Latino or Hispanic 37 (6.0) 3 (3.4) 2 (0.8)
Unknown 12 (2.0) 6 (6.8) 2 (0.8)respectively, p-value b 0.001, without outliers). However, when strati-
ﬁed by high-risk groups, WUS was only signiﬁcantly correlated with
xerostomia in SS and Sicca groups, while IUS was signiﬁcantly correlat-
ed with xerostomia in all three groups. Correlation of TSS with
xerostomia was only noted in the SS group, and was weaker than that
of WUS and IUS. Correlation coefﬁcients are inﬂuenced by outliers,
yielding weak correlations. In this analysis, even with the removal of
outliers salivary ﬂow rates remainedweakly correlatedwith xerostomia
in all three high-risk groups.
Table 3 compares the phenotypic characteristics of those with and
without xerostomia. Compared to SS participants without xerostomia
(SS+X−), SS participantswith xerostomia (SS+X+)had a signiﬁcantlytive, Native Hawaiian and other Paciﬁc Islander, multiple races, other, and unknown | Per-
X+ Sicca+ X−
p-Value
ISS+ X+ ISS+ X−
p-Value7 N = 98 N = 94 N = 153
84) 52 (21–88) 0.50a 50 (11–86) 46 (9–81) 0.06a
4) 26 (26.5) 0.007b 10 (10.6) 27 (17.7) 0.09b
.6) 72 (73.5) 84 (89.4) 126 (82.4)
.6) 77 (78.6) 0.11b 75 (79.8) 100 (65.4) 0.10b
) 9 (8.2) 7 (7.5) 25 (16.3)
4 (4.1) 5 (5.3) 12 (7.8)
8 (8.2) 7 (7.5) 16 (10.5)
.4) 91 (92.9) 0.02b 86 (91.5) 143 (93.5) 0.66b
4 (4.1) 8 (8.5) 9 (5.9)
3 (3.1) 0 (0.0) 1 (0.7)
Table 2
Xerostomia and hyposalivation (WUS, IUS) by high-risk group.
A.⁎Statistically signiﬁcant. B. In Overall, WUS had the strongest point-biserial correlation coefﬁcient (rpb =−0.49, p b 0.001) than IUS and TSS. Stratiﬁed by groups, WUS is signiﬁcantly
correlatedwith xerostomia in SS and Sicca groups; ISS is signiﬁcantly correlatedwith xerostomia in SS (rpb=−0.17, p b 0.001), Sicca (rpb=−0.20, p=0.002), and ISS (rpb=−0.18, p=
0.01) groups. Among SS participants, both unstimulated and stimulated salivary ﬂow rateswereweakly correlatedwith xerostomia reaching statistical signiﬁcance only after the removal
of outliers (WUS: rpb=−0.19, p=0.02; IUS: rpb=−0.17, p b 0.001; TSS: rpb=−0.13, p=0.002),with the exception of IUSwhich exhibited borderline signiﬁcance even in the presence
of outliers (rpb =−0.08, p = 0.04). Among Sicca participants, only unstimulated salivary ﬂow rates (WUS, IUS) showed a statistical signiﬁcant correlation, albeit weak, with xerostomia
(WUS: rpb=−0.22, p= 0.03; IUS: rpb=−0.20, p= 0.002). Among ISS participants, only IUSwas statistically signiﬁcantly correlatedwith xerostomia, which toowas a weak correlation
(rpb =−0.18, p = 0.01). Correlation of TSS with xerostomia was of statistical signiﬁcance in the SS group (rpb =−0.13, p = 0.002).
A. Test Diagnostics of Xerostomia and Hyposalivation
Test Result Disease Status Overall Total
SS+ SS− Sicca+ Sicca− ISS+ ISS−
Xerostomia+⁎ 613 351 257 707 94 870 964
Xerostomia− 88 251 98 241 153 186 339
Total 701 602 355 948 247 1056 1303
Test Diagnostics - Xerostomia SS+ (N = 701) Sicca+ (N = 355) ISS+ (N = 247)
ES 95% CI ES 95% CI ES 95% CI
Prevalence (%) 53.8 51.0–56.5 27.2 24.8–29.8 19 16.9–21.2
Sensitivity (%) 87.5 84.8–89.8 72.4 67.4–77.0 38.1 32.0–44.4
Speciﬁcity (%) 41.7 37.7–45.7 25.4 22.7–28.3 17.6 15.4–20.0
Likelihood ratio (+) 1.50⁎ 1.39–1.61 0.97 0.90–1.05 0.46⁎ 0.39–0.54
Likelihood ratio (−) 0.30⁎ 0.24–0.37 1.09 0.89–1.33 3.52⁎ 2.99–4.14
Odds ratio LR(+)/LR(−) 4.98⁎ 3.78–6.56 0.89 0.68–1.18 0.13⁎ 0.10–0.18
Positive Predictive Value (%) 63.6 60.5–66.6 26.7 23.9–29.6 9.8 8.0–11.8
Negative Predictive Value (%) 74 69.0–78.6 71.1 65.9–75.9 54.9 49.4–60.2
Test Diagnostics - Hyposalivation (WUS) SS+ (N = 177) Sicca+ (N = 104) ISS+ (N = 50)
ES 95% CI ES 95% CI ES 95% CI
Prevalence (%) 53.5 47.9–58.9 31.4 26.5–36.7 15.1 11.4–19.4
Sensitivity (%) 63.8 56.3–70.9 67.3 57.4–76.2 10 3.3–21.8
Speciﬁcity (%) 51.3 43.1–59.4 48 41.4–54.7 34.9 29.3–40.8
Likelihood ratio (+) 1.31⁎ 1.08–1.60 1.29⁎ 1.08–1.56 0.15⁎ 0.07–0.35
Likelihood ratio (−) 0.70⁎ 0.55–0.90 0.68⁎ 0.50–0.93 2.58⁎ 2.15–3.10
Odds ratio LR(+)/LR(−) 1.86⁎ 1.20–2.89 1.90⁎ 1.17–3.08 0.06⁎ 0.02–0.15
Positive Predictive Value (%) 60.1 52.7–67.2 37.2 30.3–44.6 2.7 0.9–6.1
Negative Predictive Value (%) 55.2 46.7–63.6 76.2 68.4–82.9 68.5 60.2–76.0
Test Diagnostics - Hyposalivation (IUS) SS+ (N = 667) Sicca+ (N = 257) ISS+ (N = 199)
ES 95% CI ES 95% CI ES 95% CI
Prevalence (%) 59.4 56.5–62.3 22.9 20.5–25.5 17.7 15.5–20.1
Sensitivity (%) 76 72.6–79.2 71.6 65.7–77.0 29.1 22.9–36.0
Speciﬁcity (%) 46.9 42.3–51.6 34.8 31.6–38.0 25.2 22.4–28.1
Likelihood ratio (+) 1.43⁎ 1.30–1.58 1.1 1.00–1.20 0.39⁎ 0.31–0.49
Likelihood ratio (−) 0.51⁎ 0.43–0.60 0.82 0.66–1.01 2.81⁎ 2.44–3.24
Odds ratio LR(+)/LR(−) 2.80⁎ 2.17–3.62 1.34 0.99–1.82 0.14⁎ 0.10–0.19
Positive Predictive Value (%) 67.7 64.2–71.0 24.6 21.5–27.8 7.7 5.9–9.9
Negative Predictive Value (%) 57.2 52.0–62.3 80.5 76.1–84.4 62.3 57.2–67.2
B. Point Biserial Correlation of Xerostomia and Hyposalivation
SS+ Sicca+ ISS+ Overall
Whole Unstimulated Salivary Flow Rate (WUS, ml/15min)
Xerostomia rpb =−0.09 rpb =−0.20 rpb =−0.16 rpb =−0.33
p = 0.25 p = 0.05 p = 0.27 p b 0.001
n = 177 n = 104 n = 50 n = 331
Xerostomia, without outlier inﬂuence rpb =−0.19 rpb =−0.22 rpb =−0.23 rpb =−0.49
p = 0.02 p = 0.03 p = 0.12 p b0.001
n = 166 n = 99 n = 48 n = 306
Imputed Unstimulated Salivary Flow Rate (IUS, ml/15min)
Xerostomia rpb =−0.08 rpb =−0.13 rpb =−0.09 rpb =−0.22
p = 0.04 p = 0.04 p = 0.23 p b 0.001
n = 667 n = 257 n = 199 n = 1123
Xerostomia, without outlier inﬂuence rpb =−0.17 rpb =−0.20 rpb =−0.18 rpb =−0.42
p b0.001 p = 0.002 p = 0.01 p b 0.001
n = 613 n = 242 n = 192 n = 1013
Total Stimulated Salivary Flow Rate (TSS, ml/15min)
Xerostomia rpb =−0.06 rpb =−0.11 rpb =−0.12 rpb =−0.15
p = 0.17 p = 0.08 p = 0.13 p b 0.001
n = 575 n = 230 n = 169 n = 974
Xerostomia, without outlier inﬂuence rpb =−0.13 rpb =−0.13 rpb = 0.13 rpb =−0.21
p = 0.002 p = 0.06 p = 0.08 p b 0.001
n = 557 n = 218 n = 168 n = 934
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a. WUS by Xerostomia Status, Overall b. WUS by Xerostomia Status and High-risk Groups 
c. IUS by Xerostomia Status, Overall
e. TSS by Xerostomia Status, Overall
d. IUS by Xerostomia Status and High-risk Groups
f. TSS by Xerostomia Status and High-risk Groups
Fig. 2. Salivaryﬂowrates in high-risk groups by xerostomia status. Box represents 25th, 50th (median) and 75th percentile of salivaryﬂowrate.Whiskers drawn to the smallest and largest
observations within the calculated fences. Dots represent outliers. WUS: Whole Unstimulated Salivary Flow Rate | IUS: Imputed Unstimulated Salivary Flow Rate | TSS: Total Stimulated
Salivary FlowRate | SS: Sjögren's Syndrome | ISS: Incomplete Sjögren's Syndrome | X+:Presence of xerostomia | X−: Absence of xerostomia | Panels a, c, and e represent salivaryﬂowrates
by xerostomia status in the three high-risk groups combined. Panels b, d, and f represent salivary ﬂow rates by xerostomia status stratiﬁed by high-risk group.
275M. Billings et al. / EBioMedicine 12 (2016) 270–279higher proportion of reporting ocular dryness lasting N3 months,
hyposalivation with respect to both unstimulated and stimulated sali-
vary ﬂow rates, and salivary gland swelling. Although subjective ocular
dryness was signiﬁcantly different, the proportion of objective ocular
signs was similar between subgroups. In addition, though the propor-
tion of hyposalivation (IUS, TSS) was higher in SS + X+ subgroup,Fig. 3.Median salivary ﬂow rates by disease groups. Salivary ﬂow rates expressed in ml//
15 min. ***Statistically signiﬁcantly different from other disease groups, p b 0.001. WUS:
Whole Unstimulated Salivary Flow Rate | IUS: Imputed Unstimulated Salivary Flow Rate
| TUS: Total Unstimulated Salivary Rate | TSS: Total Stimulated Salivary Flow Rate | SS:
Sjögren's Syndrome | ISS: Incomplete Sjögren's Syndrome. Median WUS of SS and Sicca
groups were comparable (p = 0.78) but lower than that of ISS group (p b 0.001 in both
Mann-Whitney tests). Median IUS, TUS, and TSS were lowest in SS group compared to
Sicca and ISS groups (p b 0.001 in each comparison). Sicca group had lower median IUS,
TUS, and TSS compared to ISS group (p b 0.001 in each comparison).the proportions of positive focus scores (≥1 per 4 mm2) and autoanti-
bodies SSA/SSB were not different between subgroups. Diabetes
mellitus, thyroid disease, and other autoimmune disorders and
extraglandular manifestations such as fatigue, anxiety, and pain were
comparable between subgroups. Potential confounders such as ciga-
rette smoking, alcohol intake and caffeine intake were similar in both
subgroups. Various classes of medications were also similar between
subgroups. Among Sicca participants, the proportions of symptomatic
dry eye, salivary gland pain, thyroid disease, and caffeine intake were
signiﬁcantly higher among those with xerostomia than those without.
Among ISS participants, the proportions of symptomatic dry eye and
thyroid disease were signiﬁcantly higher among those with xerostomia
than those without.
The results of multivariable regression analyses for independent
predictors of xerostomia in SS participants are presented in Table 4. In
a model adjusting for all potential confounders, Black/African Ameri-
cans (OR: 0.40, 95% CI: 0.23–0.68, p-value = 0.001) and Asians (OR:
0.49, 95% CI: 0.25–0.96, p-value = 0.038) were less likely to have
xerostomia compared to whites. Those with dry eye symptoms of N-
3 months were almost 6 times more likely to have xerostomia than
those without dry eye symptoms of this duration (OR: 5.80, 95% CI:
3.62–9.28, p-value b0.001). Paradoxically, those with a Van Bijsterveld
score ≥ 4 were less likely to have xerostomia (OR: 0.55, 95% CI: 0.34–
0.90, p-value = 0.017); however, the crude odds ratio was not statisti-
cally signiﬁcant. Presence of hyposalivation based on unstimulated sal-
ivary ﬂow rate (IUS), although highly signiﬁcant in the simple logistic
regression model (OR: 2.02, 95% CI: 1.24–3.27, p-value = 0.004) was
only of borderline signiﬁcance when adjusted for confounders (OR:
Table 3
Comparison of characteristics of SS, Sicca and ISS participants with and without xerostomia.
⁎Statistically signiﬁcant variables | Two-sample test of proportions | Percentages rounded to one decimal place.
Independent variable
SS+X+ SS+X−
p-Value
Sicca+ X+ Sicca+ X−
p-Value
ISS+ X+ ISS+ X−
p-Valuen % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI
Focus score ≥ 1 per 4 mm 574 97.8 96.6–99.0 84 100 – 0.17 – – – – – – – 82 93.2 87.9–98.4 137 94.5 90.8–98.2 0.69
SSA/SSB positive 282 73.8 69.4–78.2 59 84.3 75.8–92.8 0.06 – – – – – – – 14 32 21.4–42.6 24 43.8 26.6–60.9 0.24
Dry eye N 3months 527 86.4 83.7–89.1 47 62.7 51.7–73.6 b0.001⁎ 216 84 79.6–88.5 27 45 32.4–57.6 b0.001⁎ 63 67 57.5–76.5 25 28.1 18.8–37.4 b0.001⁎
Schirmer's positive 296 50 46.0–54.0 46 54.8 44.1–65.4 0.41 101 41.9 35.7–48.1 49 60.5 49.8–71.1 b0.001⁎ 2 2.8 0–6.7 17 17.5 10.0–25.1 b0.001⁎
Van B positive 233 50 45.4–54.4 41 50.6 39.7–61.5 0.9 36 21.6 15.3–27.8 18 31.6 19.5–43.6 0.13 1 1.7 0–5.1 5 7.9 1.3–14.6 0.12
Oxford positive 183 48.2 43.1–53.2 26 42.6 30.2–55.0 0.42 32 22.2 15.4–29.0 14 29.2 16.3–42.0 0.33 4 9.3 0.6–18.0 3 6.8 0–14.3 0.67
Any one ocular sign positive 387 74.3 70.5–78.0 64 82.1 73.5–90.6 0.14 130 62.8 56.2–69.4 56 77.8 68.2–87.4 0.02⁎ 5 12.2 2.2–22.2 21 36.2 23.8–48.6 0.01⁎
WUS ≤1.5 ml/15 min 93 66.4 58.6–74.3 20 54.1 38.0–70.1 0.16 62 70.5 60.9–80.0 8 50 25.5–74.5 0.12 0 0 – 5 12.5 2.3–22.7 0.24
IUS ≤1.5 ml/15 min 453 77.8 74.5–81.2 54 63.5 53.3–73.8 b0.001⁎ 142 72.8 66.6–79.1 42 67.7 56.1–79.4 0.44 19 25.3 15.5–35.2 39 31.5 23.3–39.6 0.36
TUS ≤1.5 ml/15 min 394 80.2 76.7–83.8 59 71.1 61.3–80.8 0.06 131 75.7 69.3–82.1 39 69.6 57.6–81.7 0.37 11 18.6 8.7–28.6 34 30.9 22.3–39.5 0.09
Any one unstimulated salivary ﬂow ≤1.5 ml/15 min 483 96.6 95.0–98.2 62 87.3 79.6–95.1 b0.001⁎ 156 92.9 89.0–96.8 45 90 81.7–98.3 0.51 20 69 52.1–85.8 46 62.2 51.1–73.2 0.52
TSS ≤7.5 ml/15 min 263 53.5 49.0–57.9 32 38.6 28.1–49.0 0.01⁎ 61 35.1 28.0–42.1 16 28.6 16.7–40.4 0.37 7 11.9 3.6–20.1 22 20 12.5–27.5 0.18
Salivary gland swelling 71 98.6 95.9–100.0 9 81.8 59.0–100.0 b0.001⁎ 15 93.8 81.9–100.0 5 100 – 0.57 – – – – – – –
Salivary gland pain 31 81.6 69.3–93.9 4 57.1 20.5–93.8 0.15 18 94.7 84.7–100.0 1 50 0–100.0 0.04⁎ 0 0 – 3 100 – 0.05
Fatigue 104 92.9 88.1–97.6 11 78.6 57.1–100.0 0.07 58 93.5 87.4–99.7 7 87.5 64.6–100.0 0.53 5 100 – 9 64.3 39.1–89.4 0.12
Anxiety 77 70 61.4–78.6 8 57.1 31.2–83.1 0.33 47 75.8 65.1–86.5 4 50 15.3–84.6 0.12 5 100 – 8 57.1 31.2–83.1 0.08
Pain 92 90.2 84.4–96.0 24 88.9 77.0–100.0 0.84 20 83.3 68.4–98.2 4 66.7 28.9–100.0 0.36 1 100 – 16 72.7 54.1–91.3 0.54
Thyroid disease 151 24.6 21.2–28.0 17 19.3 11.1–27.6 0.27 46 17.9 13.2–22.6 3 3.1 0–6.5 b0.001⁎ 17 18.1 10.3–25.9 8 5.2 1.7–8.8 b0.001⁎
Diabetes mellitus 13 2.1 0.9–3.3 1 1.4 0–3.4 0.54 9 3.5 1.3–5.7 4 4.1 0.2–8.0 0.79 2 2.1 0–5.0 3 2 0–4.2 0.93
Hx of other autoimmune disorder 17 2.8 1.5–4.1 5 5.7 0.8–10.5 0.14 2 0.8 0–1.9 1 1 0–3.0 0.82 2 2.1 0–5.0 7 4.6 1.2–7.9 0.32
Cigarette smoking 49 31.2 24.0–38.5 9 34.6 16.3–52.9 0.73 17 24 14.0–33.9 4 40 9.6–70.4 0.28 2 40 0–82.9 5 19.2 4.1–34.4 0.31
Alcohol intake 82 50.9 43.2–59.0 16 57.1 38.8–75.5 0.54 40 55.6 44.1–67.0 6 66.7 35.9–97.6 0.53 4 80 44.9–100.0 12 44.4 25.7–63.2 0.14
Caffeine intake N1 drink/day 99 61.5 54.0–69.0 18 62.1 44.4–79.7 0.95 46 63.9 52.8–75.0 3 30 1.6–58.4 0.04⁎ 2 40 0–82.9 11 40.7 22.2–59.3 0.98
Medications - reduce salivary ﬂow 22 3.6 2.1–5.1 1 1.1 0–3.4 0.23 2 0.8 0–1.9 0 – – 0.38 – – – – – – –
Medications - sialagogues 15 2.4 1.2–3.7 1 1.1 0–3.4 0.44 3 1.7 0–2.5 0 – – 0.28 1 1.1 0–3.1 0 0 – 0.2
Medications - extraglandular manifestations 85 14 11.1–16.6 15 17 9.2–24.9 0.43 13 5.1 2.4–7.7 3 3.1 0–6.5 0.42 1 1.1 0–3.1 6 3.9 0.8–7.0 0.19
Medications - combinations 30 5 3.2–6.6 2 2.3 0–5.4 0.27 2 0.8 0–1.9 0 – – 0.38 0 0 – 2 1.3 0–3.1 0.27
Medications - other 34 5.5 3.7–7.4 6 6.8 1.6–12.1 0.63 5 1.9 0.3–3.6 0 – – 0.16 4 1.1 0–4.8 1 2.6 0.1–5.1 0.4
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Table 4
The association between key characteristics of SS participants and xerostomia.
aFocus score - nonlinear association, spline at 2 based ondata | bBinary variableswith absence of the variable as reference | cTSS - frommultiple logistic regressionmodel replacing IUS | OR -
odds ratio | NA - variable not selected bymodel due to non-signiﬁcance/collinearity | ⁎Statistically signiﬁcant variables. Independent predictors of xerostomia among SS participants: those
with xerostomia of N3months duration are more likely to bewhite, have dry eye symptoms for N3 months, but have a lower Van Bijsterveld score (b4), have a lower stimulated salivary
ﬂow rate (≤7.5 ml/15 min), have a higher focus score (N2), and have salivary gland swelling. Non-predictors of xerostomia among SS participants: there was no statistically signiﬁcant
difference in age, gender, autoantibodies SSA/SSB, Schirmer's test, Oxford score, unstimulated parotid (OR: 1.01, 95% CI:0.87–1.16, p-value = 0.941) and submandibular (OR: 0.78, 95%
CI: 0.36–1.69, p-value= 0.526) salivary ﬂow rates (not shown in the table), extraglandular manifestations such as fatigue, anxiety, pain, past history of thyroid disease, diabetes mellitus,
other autoimmune disorders, cigarette smoking, alcohol intake, and caffeine intake between those with and without xerostomia.
Independent variable
SS+
Unadjusted models p-Value Adjusted model p-Value
OR 95% CI OR 95% CI
Age 1.02 1.01–1.04 0.004⁎ 1 0.99–1.02 0.405
Gender
Male 1 − − 1 − −
Female 1.34 0.63–2.83 0.443 1.12 0.55–2.27 0.75
Race
White 1 − − 1 − −
Black or African American 0.4 0.23–0.71 0.002⁎ 0.4 0.23–0.68 0.001⁎
Asian 0.44 0.21–0.91 0.026⁎ 0.49 0.25–0.96 0.038⁎
Other 0.64 0.27–1.51 0.311 0.62 0.27–1.39 0.243
Ethnicity
Not Latino/not Hispanic 1 − − NA − −
Latino/Hispanic 1.73 0.52–5.74 0.372 − − −
Unknown 0.28 0.10–0.77 0.013⁎ − − −
Focus scorea
Spline at 2 (crude)
Focus score ≤ 2 0.45 0.24–0.82 0.009⁎ 1 − −
Focus score N 2 1.16 1.06–1.26 0.001⁎ NA − −
Focus score N 2 (binary, ref ≤2) 2.59 1.36–4.93 0.004⁎ 1.92 1.20–3.09 0.007⁎
Autoantibodies
Neither SSA or SSB 1 − − 1 − −
Either one present 0.41 0.19–0.89 0.023⁎ 0.78 0.38–1.63 0.514
Both present 0.61 0.29–1.25 0.177 1.1 0.55–2.23 0.784
Dry eye N3 monthsb 5.35 3.32–8.61 b0.001⁎ 5.8 3.62–9.28 b0.001⁎
Schirmer's test positiveb 0.83 0.52–1.31 0.414 NA − −
Van B test positiveb 0.97 0.61–1.56 0.904 0.55 0.34–0.90 0.017⁎
Oxford test positiveb 1.25 0.72–2.16 0.422 NA − −
Hyposalivation 1.68 0.81–3.51 0.166 1.34 0.53–3.39 0.543
WUS ≤1.5 ml/15 minb
Hyposalivation 2.02 1.24–3.27 0.004⁎ 1.68 1.01–2.79 0.046⁎
IUS ≤1.5 ml/15 minb
Hyposalivation 1.65 0.98–2.79 0.06 NA − −
TUS ≤1.5 ml/15 minb
Hyposalivation 1.83 1.14–2.95 0.004⁎ 1.67 1.06–2.65 0.028⁎
TSS ≤7.5 ml/15 minc
Salivary gland swellingb 15.78 1.30–191.94 0.030⁎ 49.39 2.02–1206.3 0.017⁎
Salivary gland painb 3.32 0.60–18.31 0.168 2.55 0.39–16.64 0.327
Fatigueb 3.55 0.82–15.35 0.09 2.6 0.57–11.92 0.218
Anxietyb 1.75 0.56–5.44 0.334 NA − −
Painb 1.15 0.29–4.51 0.841 0.88 0.18–4.23 0.87
Thyroid diseaseb 1.37 0.78–2.39 0.276 NA − −
Diabetes mellitusb 1.89 0.24–14.59 0.544 NA − −
Hx of other autoimmune disorderb 0.47 0.17–1.32 0.152 NA − −
Cigarette smokingb 0.86 0.36–2.06 0.73 NA − −
Alcohol intakeb 0.78 0.35–1.75 0.544 NA − −
Caffeine intake N1 drink/dayb 0.96 0.43–2.20 0.953 NA − −
Medications
None 1 − − 1 − −
Medications that reduce salivary ﬂow 3.25 0.43–24.50 0.254 11.25 1.64–77.01 0.014⁎
Medications - sialagogues 2.21 0.29–17.04 0.446 5.32 0.86–32.89 0.072
Medications - extraglandular manifestations 0.84 0.45–1.54 0.565 1.77 0.92–3.42 0.087
Medications - combinations 2.21 0.52–9.49 0.285 6.95 1.75–27.63 0.006⁎
Medications - other 0.84 0.34–2.07 0.699 2.05 0.80–5.28 0.135
277M. Billings et al. / EBioMedicine 12 (2016) 270–2791.68, 95% CI: 1.01–2.79, p-value = 0.046). Hyposalivation based on TSS
was signiﬁcantly associated with xerostomia (OR: 1.67, 95% CI: 1.06–
2.65, p-value= 0.028). Those with a focus score N 2were twice as likely
to have xerostomia as those with a focus score of ≤2 (OR: 1.92, 95% CI:
1.20–3.09, p-value= 0.007). Salivary gland swelling was strongly asso-
ciated with xerostomia in this group (OR: 49.39, 95% CI: 2.02–1206.30,
p-value = 0.017). Those on medications that reduce salivary ﬂow
(OR: 11.25, 95% CI: 1.64–77.01, p-value = 0.014) or on a combination
of medications (OR: 6.95, 95%CI: 1.75–27.63, p-value = 0.006) weremore likely to have xerostomia than those not on any medications.
Modeling for Sicca and ISS groups are reported as SI.
4. Discussion
Xerostomia is a chief complaint of SS patients. Since dry mouth can
affect adversely oral health, overall well-being, and patient's quality of
life, it is a patient-centered outcome that should be considered in SS re-
search and disease management. In this study, we examined the
278 M. Billings et al. / EBioMedicine 12 (2016) 270–279importance of patient-reported xerostomia of N3monthsduration in in-
dividuals with SS, Sicca, and ISS. In our study population, the prevalence
of xerostomia was highest in the SS group followed by the Sicca and ISS
groups.We also found that the ability of xerostomia to screen for SSwas
greater than its ability to screen for Sicca or ISS. Furthermore, when
compared with the objective sign of hyposalivation, xerostomia had
comparable if not superior screening test utility. These screening test di-
agnostics of xerostomia are only applicable to a high risk population
(those with salivary gland dysfunction) since screening tests are more
effective herein than when applied to the general population (Gordis,
2009). These results indicate that subjective and objective measure-
ments of salivary gland dysfunction are both important in the diagnosis
and classiﬁcation of SS. The ﬁndings suggest that xerostomiamay be re-
ﬂective of a different domain of salivary gland dysfunction in SS, namely
one that comprises compositional changes of saliva.
As xerostomia of prolonged duration was associated with objective
clinical ﬁndings such as higher focus score, lower salivary ﬂow, and sal-
ivary gland swelling, it could be considered a surrogate marker of the
poorly understood disease progression of SS. We found that xerostomia
in SS participants was not attributable to age, gender, extraglandular
manifestations, or other comorbidities. In addition, autoantibodies
SSA/SSB failed to be a signiﬁcant predictor of xerostomia. Medications
with a well-documented inhibitory effect on salivary ﬂow, in combina-
tion with/without other medications, were included in the regression
models to control for their confounding effect (Porter and Scully,
2000, Sreebny and Schwartz, 1997).
It is well known that diagnostic and classiﬁcation criteria for SS need
to be improved, especially as this syndrome encompasses a spectrum of
similarly presenting diseases (Goules et al., 2014). However, classiﬁca-
tion criteria that eliminate both xerostomia and hyposalivation and as-
sess salivary dysfunction solely based on a focus score of ≥1, assume
that the pathogenesis takes on a singular pathway of dysfunctional im-
mune response, while ignoring the possibility of other pathways in the
etiopathology of salivary dysfunction and disease progression in this
complex disorder.Moreover, the diagnostic value of focus score remains
unclear. In a systematic review of 9 included studies, a focus
score ≥ 1was found to have a high speciﬁcity (61.2% to 100%) and a var-
iable sensitivity (63.5% to 93.7%). As a positive focus score is found in
healthy aged patients, a speciﬁcity of 100% would be an overestimate.
The authors concluded that their ﬁndings indicate a lack of information
about the diagnostic value of minor salivary gland biopsy (Guellec et al.,
2013).
Furthermore, such classiﬁcation criteria that select a highly speciﬁc
sub-population of SS participants (those with 2 out of 3 objective
signs - focus score ≥ 1, positive serology, and ocular staining score ≥ 3)
(Shiboski et al., 2012) could challenge external validity. Therefore, clin-
ical trial results based on such limited classiﬁcation criteriawould not be
generalizable to the entire SS population but rather to a highly speciﬁc
sub-population. Moreover, such classiﬁcation criteria have a potential
for information bias leading to differential/non-differential misclassiﬁ-
cation, and missing cases leading to an immigrative selection bias. Fur-
ther, as xerostomia is a chief oral complaint of SS participants and is of
high prevalence in this group, failure to include xerostomia in SS re-
search studies or to target its mitigation in clinical trials developing
therapeutics for SS discounts patient-centered outcomes research. Fur-
ther, others have pointed out that when symptoms are excluded from
classiﬁcation criteria, there is a higher likelihood of missing cases of
early disease who would have had a higher possibility of responding
to newer target therapies (Vitali et al., 2013).
However, this studywas not designed to develop a classiﬁcation sys-
tem for SS rather it was purposed to provide evidence to assist in the
process of developing newer classiﬁcation systems. The development
of classiﬁcation systems requires a balance between sensitivity and
speciﬁcity in order to minimize misclassiﬁcation. Furthermore, the net
speciﬁcity and net sensitivity of the entire classiﬁcation set needs to
be analyzed. This is important, especially when simultaneous testingby individual criteria is being undertaken. Therefore, there is space for
improvement in the development of classiﬁcation criteria and we look
forward to the newer classiﬁcation system (ACR-EULAR) that is in the
pipeline which is said to have incorporated both xerostomia and
hyposalivation to certain levels.
This study undertook an in-depth evaluation of xerostomia in SS.
Sicca and ISS groups were also evaluated for the purpose of a compara-
tive analysis. Various statistical analyses were performed to check for
consistency of ﬁndings, including regression modeling with the adjust-
ment for confounders; such evidence has been lacking in the literature.
Clinical characteristics of thosewith SS based on xerostomia statuswere
elucidated, which again is novel. Furthermore, this study minimized
various biases, described in the SA, that strengthen the analyses. The
lack of temporality in associations reported, as a consequence of study
design, is a study limitation. Therefore, it should not be assumed that
characteristics such as focal lymphocytic sialadenitis (focus score N 2/
mm2) preceded the development of xerostomia in SS. The other limita-
tion is the use of imputed data for whole unstimulated salivary ﬂow
rate. However, we analyzed and reported WUS without imputation
and total unstimulated salivary ﬂow rate for comparison. To the argu-
ment that there may be circularity in SS case deﬁnition and xerostomia
as a screening aid, it must be acknowledged that xerostomia is neither a
sufﬁcient nor necessary criterion in the AE classiﬁcation. Furthermore, it
is not uncommon for screening tests to also be a part of classiﬁcation
criteria, as in the case of diabetes where blood glucose concentrations
are utilized for both screening and classiﬁcation criteria (Harris, 1995).
Studies with longitudinal analyses on changes over time in various
key characteristics of SS, Sicca and ISS groups are planned for the future.
It is our intention to carry out a detailed and thorough investigation of
the trajectories of the various groups over time which is beyond the
scope of the current study as it pertains to the baseline analyses of the
data.
Our study evaluated patient-reported xerostomia of N3 months and
found it to be a signiﬁcant indicator of SS. In SS, qualitative changes in
saliva might bemore informative than quantitative salivary ﬂow. Saliva
is a complex medium that has many functions and many components
with different physical characteristics that cannot be captured by ﬂow
measurements alone. In light of our current understanding that
xerostomia causes considerable morbidity and quality of life deﬁcit in
SS patients, our ﬁndings suggest that self-reported xerostomia should
be considered in SS classiﬁcation systems and be a targetable endpoint
in SS clinical trials and research.Funding Source
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